Regeneron Partners with TriNetX for 300M Patient Data
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to...
Alzheimer’s Disease artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 Regeneron Pharmaceuticals, Inc. has announced a strategic collaboration with TriNetX to...
Princeton, N.J., November 4, 2025 – Bristol Myers Squibb (NYSE: BMY) announced a major scientific milestone with the presentation...
MORRISTOWN, N.J. | October 24, 2025 — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology-focused biopharmaceutical company pioneering next-generation antibody-drug...
SAN FRANCISCO, Calif., Oct. 7, 2025 — Verana Health announced the expansion of its MIPS Advisory Services, offering enhanced...
September 22, 2025 — Florida, USA — A recent real-world retrospective study of 359 adult patients with lower-risk myelodysplastic...
